RTP Mobile Logo
Real-Life Oncology: Case-Based Discussions on the Biopsychosocial Management of Patients with Multiple Myeloma - Proceedings from a Satellite Symposium Held in Conjunction with the 2011 Oncology Nursing Society Annual Congress
Released August 2011

A comprehensive online training resource and self-directed educational activity that includes discussions of individual patient cases highlighting the importance of biopsychosocial and other variables in clinical decision-making, a review of recent clinical research findings and an exploration of optimal therapeutic and supportive care strategies for patients with multiple myeloma.

CE Disclosures and Faculty Information


    This activity is intended for oncology nurses, nurse practitioners and clinical nurse specialists involved in the treatment of multiple myeloma.


    • Discuss the benefits and risks associated with systemic therapies used in the evidence-based treatment of multiple myeloma, including chemotherapy, proteasome inhibitors, corticosteroids and immunomodulatory agents, in the pre- and postautologous stem cell transplant settings and for patients who are not candidates for autologous stem cell transplant.
    • Develop a plan to manage the side effects associated with these therapies to support quality of life and continuation of treatment.
    • Describe the roles of cytogenetic studies and beta-2 microglobulin levels in the diagnosis of multiple myeloma, estimation of prognosis and selection of treatment.


    Research To Practice is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center’s Commission on Accreditation.

    CME credit is no longer available for this issue


    CME credit is no longer available for this issue


    CME credit is no longer available for this issue

    This CNE activity contains a video component. The participant should watch the video content.


    Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education. We assess potential conflicts of interest with faculty, planners and managers of CNE activities. Real or apparent conflicts of interest are identified and resolved through a conflict of interest resolution process. In addition, all activity content is reviewed by both a member of the RTP scientific staff and an external, independent reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.

    FACULTY — The following faculty (and their spouses/partners) reported real or apparent conflicts of interest, which have been resolved through a conflict of interest resolution process:

    Carol Ann Huff, MD
    Director, Myeloma Program
    Associate Professor of Oncology and Medicine
    Johns Hopkins University
    Baltimore, Maryland

    Advisory Committee: Amgen Inc, Bristol-Myers Squibb Company, Johnson & Johnson Pharmaceuticals, Onyx Pharmaceuticals Inc; Paid Research: Bristol-Myers Squibb Company, Geron.

    Kena C Miller, MSN, FNP

    Nurse Practitioner
    Lymphoma/Myeloma Division
    Roswell Park Cancer Institute
    Buffalo, New York

    Advisory Committee and Speakers Bureau: Celgene Corporation, Millennium: The Takeda Oncology Company.

    Noopur Raje, MD
    Director, Center for Multiple Myeloma
    Massachusetts General Hospital Cancer Center
    Associate Professor of Medicine
    Harvard Medical School
    Boston, Massachusetts 

    Advisory Committee
    : Amgen Inc, Novartis Pharmaceuticals Corporation; Consulting Agreements: Celgene Corporation, Novartis Pharmaceuticals Corporation; Research Grant: AstraZeneca Pharmaceuticals LP.

    Tiffany Richards, MS, ANP-BC, AOCNP
    Nurse Practitioner
    Department of Lymphoma/Myeloma
    The University of Texas
    MD Anderson Cancer Center
    Houston, Texas

    Consulting Agreement: Millennium: The Takeda Oncology Company; Speakers Bureau: Celgene Corporation.

    MODERATORDr Love is president and CEO of Research To Practice, which receives funds in the form of educational grants to develop CME/CNE activities from the following commercial interests: Allos Therapeutics, Amgen Inc, Astellas Pharma Global Development Inc, AstraZeneca Pharmaceuticals LP, Aureon Laboratories Inc, Bayer HealthCare Pharmaceuticals/Onyx Pharmaceuticals Inc, Biogen Idec, Boehringer Ingelheim Pharmaceuticals Inc, Bristol-Myers Squibb Company, Celgene Corporation, Cephalon Inc, Daiichi Sankyo Inc, Dendreon Corporation, Eisai Inc, EMD Serono Inc, Genentech BioOncology, Genomic Health Inc, ImClone Systems, a wholly owned subsidiary of Eli Lilly and Company, Lilly USA LLC, Millennium: The Takeda Oncology Company, Mundipharma International Limited, Myriad Genetics Inc, Novartis Pharmaceuticals Corporation, OSI Oncology, Sanofi and Seattle Genetics.

    RESEARCH TO PRACTICE STAFF AND EXTERNAL REVIEWERS — The scientific staff and reviewers for Research To Practice have no real or apparent conflicts of interest to disclose.

    This educational activity contains discussion of published and/or investigational uses of agents that are not indicated by the Food and Drug Administration. Research To Practice does not recommend the use of any agent outside of the labeled indications. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings. The opinions expressed are those of the presenters and are not to be construed as those of the publisher or grantors.

    This activity is supported by educational grants from Cephalon Inc, Genentech BioOncology and Millennium: The Takeda Oncology Company.

    Hardware/Software Requirements:
    An Internet connection that is at least 28.8 Kbps
    A monitor set to 1280 x 1024 pixels or more
    Internet Explorer 6.x or newer, Firefox 2.x or newer, or Safari 2.x or newer
    Macromedia Flash plug-in 6.0 or greater
    Adobe Acrobat Reader
    (Optional) Sound card and speakers for audio

    Last review date: August 2011
    Expiration date: August 2012


Acknowledge and close

Watch video
(WiFi is recommended for best performance):
ONS Multiple Myeloma Satellite - 2011Proceedings from a Satellite Symposium Held in Conjunction with the 2011 Oncology Nursing Society (ONS) Annual Congress